• Adarx Pharmaceuticals director Erez Chimovits reported an increase in indirect beneficial ownership to 9,292,025 common shares.
• Filing showed 61,516 shares bought in the IPO at USD 17 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adarx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000947871-26-000912), on September 30, 2026, and is solely responsible for the information contained therein.